ESR1 and breast cancer: By leveraging the ion-dependent MIDAS for binding, estradiol could potentially influence integrin-mediated signaling pathways and alter the migratory and invasive behavior of ER-positive breast cancer cells, extending the functional role of estrogen beyond classical ER-α signaling.